Washington, D.C. · Nonprofit
GLOBAL COLON CANCER ASSOCIATION
GLOBAL COLON CANCER ASSOCIATION (Washington, D.C.) receives grants from 13 organizations whose IRS filings report $599,001 to it, the largest being PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA ($485,000). 4 of them have funded it in more than one year.
- Revenue FY2024
- $888k
- Funders on record
- 13
- Grants received
- $599k
- Net assets
- $365k
What Global Colon Cancer Association does
Mission
The corporation will effectively address the issues and provide information surrounding colorectal cancer to clinicians, patients and caregivers across the globe.
As stated on its FY2024 Form 990.
Programs
Growing and supporting the international colon cancer community - the gcca now represents more than 80 not for profit organizations from 40 countries. Our membership of patient groups has increased the organization's footprint in the international patient group arena. We use social media and email to communicate with both the crc community at large and to our member groups. Having every crc group in the world makes the organization much stronger in the policy arena and when advocating on behalf of the colon cancer community. Through this work, we have gained more credibility with potential funders as well as policymakers around the globe. This has resulted in an increase in funding as well as advocacy work.
$193,262 spent26% of program spendingAdvocating for patient-centered policy - the gcca is a leader in the international policy arena, representing more than 6,000,000 colorectal cancer patients around the world. The gcca invests substantial time in representing the patient perspective to regulators, policymakers and other relevant stakeholders, including the fda, ema, who and other governing bodies wherever possible. The gcca's policy travel expenses are paid by other coalitions so the organization does not incur a great deal of expenses in comparison to the amount of work performed.
$235,549 spentof which $55,065 as grants32% of program spendingEducation - addressing the needs of the colon cancer community and the general public is the key to tackling the problems associated with colon cancer. With the disease being the most preventable major cancer through screening, educating people about screenings is a major mission of the gcca and all of its members. In 2022, we held our 4th annual virtual colorectal cancer congress, which provided critical disease education. Our know your biomarker program expanded in content and reach, as well as our clinical trial awareness program to increase participation and understanding of clinical trials. Further, the gcca attends major oncology and gastroenterology conferences where we frequently are also invited to speak, present, or otherwise educate the patient advocate community. Lastly, the gcca educates through social media and other programs we currently have where we provide forums for patient education and information exchange among patients.
$314,176 spent42% of program spending
The 3 programs described on its FY2023 Form 990, listed largest first by expense. Program spending in total: $742,987.
The organization over time
Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.
Balance sheet
Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2022 to 2023, from $339k to $468k (+38%).
How it's funded, over time
Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.
100% of GLOBAL COLON CANCER ASSOCIATION’s revenue is contributions — more donation-reliant than the typical peer (82% for the typical peer).
Surplus & reserves
Operating surplus or deficit each year, and months of liquidity in hand. 2 of the last 8 reported years ran a deficit.
reserve
Leadership and staff
The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.
Chief executive
Andrew Spiegel
CEO
As listed on its FY2024 Form 990.
Who funds it, year by year
2017 → 2023: the base broadened from 2 funders to 3 funders, grant income rose $60k → $147k.
5 of 13 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 8% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.
From the IRS filings of GLOBAL COLON CANCER ASSOCIATION’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How concentrated its funding is
GLOBAL COLON CANCER ASSOCIATION leans on a few funders — its largest provides 81% of grant income and the top three 89%; half comes from just 1 funder.
the vertical line marks half of all grant income — 1 funder to its left
92% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund GLOBAL COLON CANCER ASSOCIATION.
Largest funder’s share by year: 2017 58% · 2018 100% · 2019 100% · 2020 100% · 2021 100% · 2022 50% · 2023 95% — growing more concentrated.
“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
How long its funders stay
50% of GLOBAL COLON CANCER ASSOCIATION's funders are still giving 3 years after their first grant; 31% give in more than one year at all.
Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.
Where its funders are
88% of GLOBAL COLON CANCER ASSOCIATION's grant income comes from Washington, D.C. funders.
In-state vs out-of-state, by year
Funder states come from each funder’s own filing. $46k arriving through sponsors registered in 4 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.
Against its field
GLOBAL COLON CANCER ASSOCIATION has grown faster than three-quarters of the 13,754 health nonprofits its size.
this organization peer median middle 50% of peers· 13,754 health nonprofits $100k–$1M, FY2024
Organizations like GLOBAL COLON CANCER ASSOCIATION
Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.
In Washington, D.C.
Nationally
Read directly from this organization’s own Form 990, as neutral context.
Where the money goes
98% of spending goes to programs.
Governance
Public support
31%
Share of support from the public (Schedule A) — the basis for its public-charity status.
Screen this organization
A dated, signed PDF of the compliance screen for GLOBAL COLON CANCER ASSOCIATION: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.
Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf
Questions and answers
- Who funds GLOBAL COLON CANCER ASSOCIATION?
- GLOBAL COLON CANCER ASSOCIATION (Washington, D.C.) receives grants from 13 organizations whose IRS filings report $599,001 to it, the largest being PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA ($485,000). 4 of them have funded it in more than one year.
- How many funders does GLOBAL COLON CANCER ASSOCIATION have?
- IRS filings report 13 organizations giving $599,001 in grants to GLOBAL COLON CANCER ASSOCIATION, 4 of which have funded it in more than one year.
- Who is the largest funder of GLOBAL COLON CANCER ASSOCIATION?
- PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA is the largest funder on record, with $485,000 in grants. The full list of funders is on this page.
- How can an organization like GLOBAL COLON CANCER ASSOCIATION find more funders?
- Start with the funders already giving here, then look at the foundations that back similar organizations in Washington, D.C.. The funding by cause and by state pages list the largest funders for a given area and how to approach them.
Play a game about who funds Global Colon Cancer Association →
These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 13 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing